Does Fallon Community Health Plan (FCHP) Cover Viagra?

How FCHP Handles Erectile Dysfunction Drug Coverage

FCHP does not publish a single universal formulary that covers all members identically. Coverage depends on which specific plan you hold: commercial HMO, PPO, Medicare Advantage, or MassHealth Medicaid. Generic sildenafil has a reasonable chance of appearing on commercial formularies at Tier 2 or Tier 3, but brand Viagra is almost always excluded or placed at a non-preferred tier requiring prior authorization.

Why Plan Type Changes Everything

Commercial employer-sponsored plans have the broadest flexibility. FCHP can negotiate with employers to include or exclude ED medications, meaning two members both holding "FCHP HMO" cards may have different formulary tiers depending on their employer's benefits design.

Medicare Advantage plans operated by FCHP are constrained by federal law. The Medicare Modernization Act of 2003 explicitly prohibits Part D coverage of drugs used to treat erectile dysfunction when prescribed solely for that indication. This is codified at 42 CFR §1001.952 and confirmed by CMS guidance. If your FCHP plan includes Medicare Part D drug benefits, sildenafil for ED is almost certainly excluded regardless of tier. CMS Medicare Part D coverage exclusions are detailed by the FDA here.

MassHealth (Medicaid) administered through FCHP follows the MassHealth Covered Outpatient Drug List, which generally does not include ED medications for the general adult population.

What the FDA Label Says About Sildenafil Indications

The FDA approved sildenafil under the brand name Viagra in March 1998 specifically for erectile dysfunction in adult men. A separate formulation, Revatio (sildenafil 20 mg), carries FDA approval for pulmonary arterial hypertension (PAH). FDA approval history for sildenafil is indexed here. Insurance plans, including FCHP, may apply different formulary rules depending on which indication is documented on the prescription. A prescription written for PAH (ICD-10 I27.0) rather than ED may receive broader coverage, but prescribing for a non-indicated diagnosis solely to gain coverage is fraudulent and illegal.

The Clinical Case for Treating Erectile Dysfunction

ED is not a cosmetic inconvenience. It affects roughly 30 million men in the United States according to NIH prevalence data, and it functions as an early warning sign for cardiovascular disease. Men with ED have a significantly elevated risk of major adverse cardiac events. A 2011 meta-analysis published in the Journal of the American College of Cardiology (N=92,757) found that ED was associated with a 44% increased risk of cardiovascular events (HR 1.44, 95% CI 1.27 to 1.63) compared with men without ED. That analysis is indexed on PubMed here.

PDE5 Inhibitors: Mechanism and Approved Options

Sildenafil, tadalafil, vardenafil, and avanafil all work by inhibiting phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic guanosine monophosphate (cGMP) in penile smooth muscle. Elevated cGMP relaxes smooth muscle and increases arterial blood flow in response to sexual stimulation. None of these drugs cause an erection without sexual arousal. That distinction matters clinically because patients with psychogenic ED may respond differently than those with vasculogenic ED.

The four FDA-approved PDE5 inhibitors differ primarily in onset and duration:

• Sildenafil (Viagra, generic): onset 30 to 60 minutes, duration 4 to 6 hours, dose range 25 mg to 100 mg
• Tadalafil (Cialis, generic): onset 30 minutes, duration up to 36 hours, dose range 5 mg to 20 mg; also FDA-approved at 5 mg daily for benign prostatic hyperplasia (BPH)
• Vardenafil (Levitra, generic): onset 30 to 60 minutes, duration 4 to 5 hours, dose range 5 mg to 20 mg
• Avanafil (Stendra): onset as fast as 15 minutes, duration 6 to 12 hours, dose 50 mg to 200 mg; generic not yet widely available

The FDA's full prescribing information for sildenafil is available here.

What Clinical Trials Show About Sildenafil Efficacy

The original registration trials for Viagra submitted to the FDA demonstrated clinically meaningful improvement in erectile function. A key randomized controlled trial published in the New England Journal of Medicine (N=532) found that 69% of sildenafil-treated patients reported improved erections vs. 22% in the placebo group (P<0.001). That NEJM trial is available here.

Tadalafil 5 mg daily has also demonstrated efficacy for both ED and lower urinary tract symptoms from BPH. A Cochrane review of PDE5 inhibitors for ED (52 trials, N=9,656) confirmed that all approved PDE5 inhibitors produced statistically significant improvement in IIEF-EF domain scores versus placebo, with similar efficacy across agents. That Cochrane review is available here.

Prior Authorization for Viagra and Sildenafil Under FCHP

Prior authorization (PA) is the process through which FCHP requires your prescribing clinician to submit clinical documentation before the plan will approve a drug for coverage. For brand Viagra, PA is almost always required. For generic sildenafil, PA may or may not be required depending on your plan tier structure.

What FCHP Typically Requires in a PA Request

When a PA is required, FCHP's pharmacy department will generally look for:

1. A confirmed diagnosis of erectile dysfunction documented in the medical record (ICD-10 N52.x).
2. Evidence that organic causes have been considered or evaluated (vascular, neurologic, hormonal).
3. Any relevant comorbidities: diabetes mellitus, hypertension, hypogonadism, or history of radical prostatectomy.
4. Confirmation that the patient is not taking medications that contraindicate PDE5 inhibitors, particularly organic nitrates (nitroglycerin, isosorbide mononitrate), which can cause life-threatening hypotension when combined with sildenafil. The FDA's drug interaction warning for sildenafil and nitrates is detailed in the label here.
5. Documentation of a reasonable trial period or clinical rationale for the specific agent requested.

Quantity Limits: The Hidden Coverage Restriction

Even when sildenafil is covered, FCHP and most commercial insurers impose quantity limits. Six to eight tablets per 30-day supply is the most common limit. This reflects the actuarial assumption that a patient uses the drug for partnered sexual activity rather than daily dosing. For patients who require daily tadalafil 5 mg for combined ED and BPH, quantity limits work differently because the daily-use indication may be treated separately under coverage rules for BPH.

How to Check Your Specific FCHP Formulary

No single answer applies to every FCHP member. These are the four reliable methods to confirm your coverage:

Method 1: FCHP Online Member Portal

Log into your FCHP member account at fchp.org. Manage to "My Benefits" and then "Drug Coverage / Formulary." Search for sildenafil or Viagra. The portal will display your tier, copay, any PA requirements, and quantity limits in real time.

Method 2: Call FCHP Member Services Directly

FCHP member services can be reached at 1-800-868-5200 (TTY: 711). Have your member ID, the drug name and dose, the prescribing physician's NPI, and the ICD-10 diagnosis code (N52.9 for ED, unspecified) ready before you call. Ask specifically: "Is prior authorization required for sildenafil 50 mg for erectile dysfunction under my plan?"

Method 3: Ask Your Pharmacist to Run a Test Claim

Any FCHP-contracted pharmacy can run a test adjudication of your prescription before you pay. This is the fastest way to see your actual out-of-pocket cost. The pharmacist will see immediately whether the claim requires PA or hits a quantity limit.

Method 4: Request a Coverage Determination in Writing

Under Massachusetts state insurance regulations and federal ACA rules, you have the right to request a formal coverage determination in writing. FCHP must respond within 72 hours for urgent requests or 30 days for standard requests. This is the appropriate step when you have been denied and want a documented answer you can appeal.

Cost of Sildenafil Without or With FCHP Coverage

Brand Viagra Retail Price

Brand Viagra 100 mg (30 tablets) retails for approximately $450 to $550 at most Massachusetts pharmacies as of 2025. Without FCHP coverage, this is the price you pay. With coverage and a non-preferred tier copay, you might pay $100 to $150 depending on your plan design.

Generic Sildenafil Price

Generic sildenafil entered the US market in December 2017 when Pfizer's patent exclusivity expired for certain manufacturers. As of 2025, generic sildenafil 100 mg (30 tablets) retails for $30 to $80 at most pharmacies. GoodRx coupons can reduce this further to $15 to $40 at specific chains. At these prices, generic sildenafil may cost less out-of-pocket through a discount card than through your FCHP copay, particularly if your plan places it on Tier 3 with a $50 copay.

NIH MedlinePlus provides drug cost comparison resources here.

When a GoodRx Coupon Beats Insurance

Discount prescription programs like GoodRx operate outside insurance billing. When your FCHP Tier 3 copay for sildenafil is $50 per fill and GoodRx pricing at a nearby CVS is $18, you pay less by using the discount card and not billing insurance at all. The trade-off is that the purchase does not count toward your FCHP deductible or out-of-pocket maximum.

Alternatives to Viagra That FCHP May Cover More Readily

If brand Viagra is excluded from your formulary, these alternatives merit discussion with your prescribing clinician:

Generic Tadalafil (Generic Cialis)

Tadalafil 5 mg daily is FDA-approved for both ED and BPH. When prescribed for BPH (ICD-10 N40.x), it may be covered under different formulary rules than when prescribed for ED alone. Generic tadalafil entered the US market in 2018. A 30-day supply of tadalafil 5 mg generic costs $20 to $60 without insurance. FDA approval for tadalafil is documented here.

Testosterone Therapy for Hypogonadal Men with ED

Approximately 35% of men with ED have concurrent hypogonadism (serum total testosterone below 300 ng/dL using the 2018 American Urological Association threshold). The 2018 AUA guideline on male hypogonadism states: "Clinicians should offer testosterone therapy to symptomatic testosterone-deficient men with hypogonadism." The AUA guideline is available through the NIH here. Testosterone replacement therapy (TRT), when prescribed for hypogonadism, often receives better insurance coverage than PDE5 inhibitors because it treats an endocrine deficiency rather than a functional complaint. TRT does not replace PDE5 inhibitor therapy but may improve response to sildenafil in hypogonadal men.

Vacuum Erection Devices and Penile Injections

Vacuum erection devices (VEDs) are covered under Medicare Part B as durable medical equipment (HCPCS code A4556 for vacuum erection device systems), which is a notable exception to the Medicare Part D ED drug exclusion. FCHP Medicare Advantage members who cannot obtain sildenafil coverage may find VED coverage available through their medical benefit rather than pharmacy benefit.

Intracavernosal injection therapy with alprostadil (Caverject, Edex) or trimix (alprostadil plus phentolamine plus papaverine) may also be covered under the medical benefit as an in-office procedure or via self-injection training. FDA labeling for alprostadil for injection is here.

Appealing a Coverage Denial from FCHP

FCHP is required under Massachusetts law and the ACA to have a formal internal appeal process. If your PA for sildenafil or Viagra is denied, you have these options:

Internal Appeal

You or your prescribing clinician may file an internal appeal within 180 days of the denial. Your clinician should submit a peer-to-peer review request, which involves speaking directly with FCHP's medical director or pharmacy director. Peer-to-peer reviews overturn ED drug PA denials at a meaningful rate when the clinician documents cardiovascular risk factors, prior therapy failure, and the medical necessity for the specific agent.

External Review

If the internal appeal is denied, Massachusetts state law requires FCHP to offer an external independent medical review through the Massachusetts Office of Patient Protection. The external reviewer is not employed by FCHP and applies clinical standards rather than formulary rules.

The Massachusetts Division of Insurance oversees health plan appeals under M.G.L. Chapter 176O, which aligns with federal ACA external review standards documented by CMS.

Exception Request for Non-Formulary Brand Viagra

Even if brand Viagra is excluded from your formulary entirely, you may request a formulary exception. This requires your prescribing clinician to document that generic sildenafil and other covered alternatives are clinically inappropriate for you specifically. This is a high bar, but men with documented adverse reactions to excipients in generic formulations or documented treatment failure at maximum doses of covered alternatives may qualify.

Cardiovascular Safety Considerations Before Starting Sildenafil

Before prescribing any PDE5 inhibitor, clinicians should assess cardiovascular risk using the Princeton III Consensus criteria, which stratify men into low, intermediate, and high risk for sexual activity and PDE5 inhibitor use. The Princeton III Consensus Panel recommendations are summarized via NIH here.

The absolute contraindication is concurrent use of any organic nitrate. Sildenafil potentiates the hypotensive effect of nitrates by inhibiting cGMP degradation in vascular smooth muscle. Men taking nitroglycerin sublingual tablets, nitroglycerin patches, or long-acting nitrates such as isosorbide mononitrate should not use sildenafil at all. This is not a relative contraindication, it is absolute.

Alpha-blockers (tamsulosin, doxazosin) used for BPH can also lower blood pressure and may have additive hypotensive effects with sildenafil. The FDA label recommends initiating sildenafil at the lowest dose (25 mg) in patients already stabilized on an alpha-blocker. FDA guidance on this interaction is in the sildenafil prescribing information.

Men with resting hypotension (systolic BP <90 mmHg), recent stroke or myocardial infarction within 6 months, unstable angina, or severe hepatic impairment should not use sildenafil until these conditions are stabilized and a physician clears them.

What to Tell Your FCHP-Affiliated Prescriber

When you visit a clinician to discuss erectile dysfunction and potential Viagra or sildenafil coverage through FCHP, bring the following to the appointment:

• Your FCHP member ID card (both sides).
• A list of all current medications including supplements and recreational drugs, particularly poppers (amyl nitrite), which interact fatally with PDE5 inhibitors. CDC resources on recreational drug interactions are available here.
• Your most recent testosterone level if previously tested (specify free and total testosterone, drawn fasting between 7 and 10 AM).
• Any prior ED medication trials: agent, dose, number of attempts, sexual stimulation context, and reason for discontinuation.
• Blood pressure reading from the past 6 months.

Your prescriber should document the ED diagnosis explicitly in the visit note using ICD-10 N52.x, specify organic vs. Psychogenic etiology where determinable, and note any cardiovascular risk factors. This documentation is what FCHP's PA reviewers use to make the coverage decision.